Lymphoma/CLL Highlights: ASH 2021

CME

Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: May 10, 2022

Expiration: May 09, 2023

John M. Burke
John M. Burke, MD
Peter Martin
Peter Martin, MD

Activity

Progress
1
Course Completed

In this module, John M. Burke, MD, and Peter Martin, MD, discuss key findings in lymphoma and chronic lymphocytic leukemia (CLL) presented at the 2021 American Society of Hematology Annual Meeting, including updates in large B-cell lymphoma, adult T-cell leukemia/lymphoma (ATL), and follicular lymphoma (FL).

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with lymphoma or CLL do you provide care for in a typical month?

In your current clinical practice, which of the following CAR T-cell therapies would you consider as a currently approved second-line option for an adult patient with large B-cell lymphoma and relapse within 1 year of first-line chemoimmunotherapy?

Which of the following patients with relapsed lymphoma would you consider discussing potential enrollment on a clinical trial with valemetostat, a novel EZH1/2 inhibitor, based on promising evidence of efficacy and safety presented by Yoshimitsu and colleagues?

Which of the following findings was reported from an updated analysis of the phase II ELARA trial that evaluated tisagenlecleucel (tisa-cel) in patients with high-risk, R/R FL with a median follow-up of 17 months?

The randomized phase III GLOW trial compared ibrutinib plus venetoclax with chlorambucil plus obinutuzumab in older or unfit patients with previously untreated CLL. Which of the following best describes the relative PFS outcomes reported from this study for patients treated with ibrutinib plus venetoclax who did not achieve undetectable measurable residual disease (MRD) compared with patients treated with chlorambucil plus obinutuzumab who did achieve undetectable MRD?